The Antitumoral Effect of Endostatin and Angiostatin Is Associated With a Down-Regulation of Vascular Endothelial Growth Factor Expression in Tumor Cells

Hajitou, Amin; Grignet-Debrus, Christine; Devy, Laetitia; Deroanne, Christophe; Bajou, Khalid; Blacher, Silvia; Fong, Tim; Chiang, Y. Jeffrey; Foidart, J.M.; Noël, Agnès

doi:10.1136/ijgc-00009577-200303001-00224

Cited by 17 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4c). This is in agreement with a recent work of Hajitou et al (2002), who reported that the antiangiogenic activity of endostatin was related to the level of VEGF down-regulation both at mRNA and protein levels. VEGF is an important multifunctional cytokine that promotes developmental, physiological, and pathological neovascularization (Carmeliet et al 1996;Ferrara et al 1996).…”

Section: Discussionsupporting

confidence: 94%

Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion

Fang¹,

Chen²,

Wu³

et al. 2009

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 94%

Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion

Fang¹,

Chen²,

Wu³

et al. 2009

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…However, its mechanism of action is still not completely understood. Recently, some studies have clearly shown endostatin to down-regulate VEGF-A expression [20], block VEGF-mediated signaling interaction with KDR/Flk-1 (VEGFR-2) [21] and suppress the activation of MMP-2, -9, and -13 [22][23][24].…”

Section: Discussionmentioning

confidence: 99%

Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells

Fukumoto

Morifuji

Katakura

et al. 2005

Clin Exp Metastasis

View full text Add to dashboard Cite

Anti-angiogenic therapy is a newly developed treatment method for malignant tumors. Endostatin has an anti-angiogenetic effect. Endostatin has also been shown to block the growth and metastasis of various cancers through the vascular system. However, there have so far been few reports on the relationship between endostatin and lymph node metastasis. In this study, we investigated the relationship between endostatin and the inhibition of lymph node metastasis. We first made recombinant adenovirus which expressed endostatin gene (Ad-end), and then performed the following experiments. Our findings showed Ad-end to inhibit the proliferation and tube formation of endothelial cells in vitro. In addition, Ad-end inhibited the growth of a human oral squamous cell carcinoma cell line (SQUU-B) implanted subcutaneously in the right flank of nude mice and orthotopically in the tongue of nude mice, and Ad-end also inhibited lymph node metastasis in orthotopic implantation. The number of CD31-positive blood vessels and 5'-nase-positive lymphatic vessels around Ad-end-infected tumors in tongue lesions was significantly lower than that in the control group. The down-regulation of vascular endothelial growth factor C (VEGF-C) in Ad-end-infected SQUU-B cells was recognized by reverse transcription-polymerase chain reaction (RT-PCR) and Western blot analysis. These findings suggested that endostatin inhibited lymphangiogenesis and lymph node metastasis by suppressing the production of VEGF-C in tumor cells.

show abstract

“…In fact, an upregulation of MMP-2 and -9 in the human diabetic arterial vasculature, with secondary increase of angiostatin expression, has been shown suggesting that enhanced angiostatin production, a potent anti-angiogenic factor that antagonizes the expression and the angiogenic effects of VEGF [61,62], may explain the impaired angiogenesis of diabetes [63].…”

Section: Mmps and Diabetesmentioning

confidence: 96%

Matrix metalloproteinases and peripheral arterial disease

et al. 2009

View full text Add to dashboard Cite

Matrix metalloproteinases (MMPs), a family of enzymes that degrade extracellular matrix, are emerging as important modulators of atherothrombosis. MMPs are produced by inflammatory cells; some of them are also released by activated platelets and play a crucial role in the remodeling processes, leading to atherosclerotic plaque formation, plaque rupture, arterial aneurysm development, and critical limb ischemia. Independent from their matrix degrading activity, MMPs also regulate some cell functions relevant to atherothrombosis, such as platelet activation, neutrophil activation, and vascular reactivity. Plasma levels of some MMPs are increasingly being recognized as a biomarker of atherosclerosis and cardiovascular risk. In peripheral arterial disease, MMPs have been shown to be involved in angiogenesis, arteriogenesis, and the development of arterial calcifications. Increased plasma levels of some MMPs (MMP-2, MMP-9) have been correlated with PAD development and severity. Single nucleotide polymorphisms of the genes encoding for some MMPs have also been associated with the risk of developing peripheral arterial disease and critical limb ischemia. Large prospective observational studies are needed to further demonstrate the role of MMPs in PAD. In perspective, pharmacologic targeting of the expression or activity of MMPs may represent a novel, attractive approach for the treatment of peripheral arterial disease.

show abstract

The Antitumoral Effect of Endostatin and Angiostatin Is Associated With a Down-Regulation of Vascular Endothelial Growth Factor Expression in Tumor Cells

Cited by 17 publications

References 0 publications

Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion

Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion

Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells

Matrix metalloproteinases and peripheral arterial disease

Contact Info

Product

Resources

About